Literature DB >> 15763140

Pharmacological profile of radioligand binding to the norepinephrine transporter: instances of poor indication of functional activity.

Maarten E A Reith1, Lijuan C Wang, Aloke K Dutta.   

Abstract

Binding assays for the norepinephrine (NE) transporter (NET) with [3H]nisoxetine have generally yielded weak potencies for compounds related to cocaine and 1-(2-(di(4-fluorophenyl)-methoxy)-ethyl)-4-(3-phenylpropyl)piperazine (GBR 12909), as compared with their functional activity in inhibiting NE uptake. In the present work with HEK-293 cells expressing the human NET (hNET), potential underlying causes for this discrepancy have been addressed: ambient temperature of the binding assay, buffer in the assay, preparation used for source of the NET, and radioligand. The results indicate that the standard [3H]nisoxetine binding assay at 0 degrees C with cell membrane preparations in high Na+ buffer underestimates the functional potency of compounds related to cocaine and GBR 12909; in drug development studies it is advisable to either carry out [3H]nisoxetine binding assays with intact cells under uptake conditions, or perform classical [3H]NE uptake studies with intact cells (or with synaptosomes from brain tissue).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15763140     DOI: 10.1016/j.jneumeth.2004.09.015

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  7 in total

1.  Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.

Authors:  Juan Zhen; Solav Ali; Aloke K Dutta; Maarten E A Reith
Journal:  J Neurosci Methods       Date:  2011-09-12       Impact factor: 2.390

2.  Novel C-1 substituted cocaine analogs unlike cocaine or benztropine.

Authors:  Maarten E A Reith; Solav Ali; Audrey Hashim; Imran S Sheikh; Naresh Theddu; Narendra V Gaddiraju; Suneet Mehrotra; Kyle C Schmitt; Thomas F Murray; Henry Sershen; Ellen M Unterwald; Franklin A Davis
Journal:  J Pharmacol Exp Ther       Date:  2012-08-15       Impact factor: 4.030

3.  Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters.

Authors:  Bipasha Guptaroy; Rheaclare Fraser; Aalisha Desai; Minjia Zhang; Margaret E Gnegy
Journal:  Mol Pharmacol       Date:  2010-12-13       Impact factor: 4.436

4.  [3H]Dopamine Uptake through the Dopamine and Norepinephrine Transporters is Decreased in the Prefrontal Cortex of Transgenic Mice Expressing HIV-1 Transactivator of Transcription Protein.

Authors:  Matthew Strauss; Bernadette O'Donovan; Yizhi Ma; Ziyu Xiao; Steven Lin; Michael T Bardo; Pavel I Ortinski; Jay P McLaughlin; Jun Zhu
Journal:  J Pharmacol Exp Ther       Date:  2020-05-27       Impact factor: 4.030

5.  The role of cysteines and histidins of the norepinephrine transporter.

Authors:  Birger Wenge; Heinz Bönisch
Journal:  Neurochem Res       Date:  2013-03-23       Impact factor: 3.996

6.  Irreversible binding of a novel phenylisothiocyanate tropane analog to monoamine transporters in rat brain.

Authors:  Vishakantha Murthy; Huw M L Davies; Simon J Hedley; Steven R Childers
Journal:  Biochem Pharmacol       Date:  2007-04-27       Impact factor: 5.858

7.  Consequences of Acute or Chronic Methylphenidate Exposure Using Ex Vivo Neurochemistry and In Vivo Electrophysiology in the Prefrontal Cortex and Striatum of Rats.

Authors:  Mathieu Di Miceli; Asma Derf; Benjamin Gronier
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.